ID   CLE2B_CONCL             Reviewed;          67 AA.
AC   D6C4J0;
DT   25-JAN-2012, integrated into UniProtKB/Swiss-Prot.
DT   13-JUL-2010, sequence version 1.
DT   25-MAY-2022, entry version 18.
DE   RecName: Full=Conotoxin Cl14.2b {ECO:0000303|PubMed:20363338};
DE   AltName: Full=Cal14.2b {ECO:0000303|PubMed:34440140};
DE   Flags: Precursor;
OS   Californiconus californicus (California cone) (Conus californicus).
OC   Eukaryota; Metazoa; Spiralia; Lophotrochozoa; Mollusca; Gastropoda;
OC   Caenogastropoda; Neogastropoda; Conoidea; Conidae; Californiconus.
OX   NCBI_TaxID=1736779;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=20363338; DOI=10.1016/j.ympev.2010.03.029;
RA   Biggs J.S., Watkins M., Puillandre N., Ownby J.P., Lopez-Vera E.,
RA   Christensen S., Moreno K.J., Bernaldez J., Licea-Navarro A., Corneli P.S.,
RA   Olivera B.M.;
RT   "Evolution of Conus peptide toxins: analysis of Conus californicus Reeve,
RT   1844.";
RL   Mol. Phylogenet. Evol. 56:1-12(2010).
RN   [2]
RP   FUNCTION, AND SYNTHESIS OF 51-67.
RX   PubMed=34440140; DOI=10.3390/biomedicines9080936;
RA   Lugo-Fabres P.H., Otero-Sastre L.M., Bernaldez-Sarabia J.,
RA   Camacho-Villegas T.A., Sanchez-Campos N., Serrano-Bello J., Medina L.A.,
RA   Muniz-Hernandez S., de la Cruz L., Arenas I., Barajas-Martinez A.,
RA   Garcia D.E., Nunez-Garcia L., Gonzalez-Canudas J., Licea-Navarro A.F.;
RT   "Potential therapeutic applications of synthetic conotoxin s-Cal14.2b,
RT   derived from Californiconus californicus, for treating type 2 diabetes.";
RL   Biomedicines 9:0-0(2021).
CC   -!- FUNCTION: Increases calcium current amplitude through Cav1.2/Cav1.3
CC       channels in rat pancreatic beta-cells, which is a prerequisite for
CC       eliciting insulin secretion. Stimulates insulin secretion in NIT-1
CC       insulinoma cell lines. In vivo, significantly decreases mice blood
CC       glucose levels as of 45 minutes after treatement, similarly to insulin
CC       treatment. Has a potential therapeutic use in endocrinal pathologies
CC       such as early stages of type 2 diabetes where the pancreas's capability
CC       to produce insulin is still effective. {ECO:0000269|PubMed:34440140}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000305|PubMed:34440140}.
CC   -!- TISSUE SPECIFICITY: Expressed by the venom duct.
CC       {ECO:0000305|PubMed:34440140}.
CC   -!- DOMAIN: The cysteine framework is XIV (C-C-C-C). {ECO:0000305}.
CC   -!- PTM: Contains 2 disulfide bonds. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the conotoxin L superfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; FJ959132; ADB93102.1; -; Genomic_DNA.
DR   AlphaFoldDB; D6C4J0; -.
DR   ConoServer; 4018; Cal14.2b precursor.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0090729; F:toxin activity; IEA:UniProtKB-KW.
PE   3: Inferred from homology;
KW   Cleavage on pair of basic residues; Disulfide bond; Neurotoxin; Secreted;
KW   Signal; Toxin.
FT   SIGNAL          1..20
FT                   /evidence="ECO:0000255"
FT   PROPEP          21..48
FT                   /evidence="ECO:0000305|PubMed:34440140"
FT                   /id="PRO_0000415016"
FT   PEPTIDE         51..67
FT                   /note="Conotoxin Cl14.2b"
FT                   /evidence="ECO:0000305|PubMed:20363338"
FT                   /id="PRO_0000415017"
SQ   SEQUENCE   67 AA;  7361 MW;  DED89C3D171F764A CRC64;
     MNVTVMFLVL LLLTMPLTDG FNIRATNGGE LFGPVQRDAG NVLDHGFQRR RECPPRCPTS
     HCNAGTC